STOCKHOLM, Feb. 5, 2026 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter and full year of 2025.
Fourth Quarter 2025
- Total revenue increased 5 per cent, 16 per cent at CER1, to SEK 7,821 M (7,436)
- Haematology revenue increased 25 per cent at CER to SEK 5,143 M (4,487), mainly driven by strong sales of Altuvoct of SEK 1,023 M (302) and of Doptelet of SEK 1,508 M (1,147), somewhat offset by lower sales of Vonjo of SEK 327 M (416)
- Immunology revenue increased 2 per cent at CER to SEK 2,337 M (2,564), driven by strong sales of Gamifant of SEK 763 M (512) and Kineret sales of SEK 741 M (777), offset by lower Beyfortus royalty of SEK 849 M (1,207)
- Revenue from the strategic portfolio1 grew by 37 per cent at CER to SEK 5,059 M (4,099)
- The adjusted EBITA margin1,2 was 41 per cent (34), excluding IAC2 of SEK -142 M. EBITA1 was SEK 3,075 M (2,572), corresponding to a margin of 39 per cent (35). EBIT was SEK 2,358 M (1,662)
- Earnings per share …